{"id":"https://openalex.org/W4361883236","doi":"https://doi.org/10.1158/1078-0432.22451901","title":"Supplementary Figures 1 - 2 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study","display_name":"Supplementary Figures 1 - 2 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361883236","doi":"https://doi.org/10.1158/1078-0432.22451901"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22451901","doi":"https://doi.org/10.1158/1078-0432.22451901","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451901","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.22451901","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039864062","display_name":"Amar J. Gajjar","orcid":"https://orcid.org/0000-0001-5019-0699","observed_orcids":["https://orcid.org/0000-0001-5019-0699"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amar Gajjar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043293908","display_name":"Clinton F. Stewart","orcid":"https://orcid.org/0000-0002-1546-9720","observed_orcids":["https://orcid.org/0000-0002-1546-9720"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Clinton F. Stewart","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071632296","display_name":"David W. Ellison","orcid":"https://orcid.org/0000-0003-1239-7757","observed_orcids":["https://orcid.org/0000-0003-1239-7757"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David W. Ellison","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112466226","display_name":"Sue Creviston Kaste","orcid":"https://orcid.org/0000-0003-4982-4118","observed_orcids":["https://orcid.org/0000-0003-4982-4118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sue Kaste","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042463331","display_name":"Larry E. Kun","orcid":"https://orcid.org/0000-0003-0386-419X","observed_orcids":["https://orcid.org/0000-0003-0386-419X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Larry E. Kun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025567999","display_name":"Roger J. Packer","orcid":"https://orcid.org/0000-0001-9413-7531","observed_orcids":["https://orcid.org/0000-0001-9413-7531"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roger J. Packer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071378074","display_name":"Stewart Goldman","orcid":"https://orcid.org/0000-0003-0134-1352","observed_orcids":["https://orcid.org/0000-0003-0134-1352"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stewart Goldman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083288793","display_name":"Murali Chintagumpala","orcid":"https://orcid.org/0000-0003-2686-6737","observed_orcids":["https://orcid.org/0000-0003-2686-6737"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Murali Chintagumpala","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Dana Wallace","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dana Wallace","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082874698","display_name":"Naoko Takebe","orcid":"https://orcid.org/0000-0002-5790-4954","observed_orcids":["https://orcid.org/0000-0002-5790-4954"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naoko Takebe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110213508","display_name":"James M. Boyett","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James M. Boyett","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083891481","display_name":"Richard J. Gilbertson","orcid":"https://orcid.org/0000-0001-7539-9472","observed_orcids":["https://orcid.org/0000-0001-7539-9472"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard J. Gilbertson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5006841058","display_name":"Tom Curran","orcid":"https://orcid.org/0000-0003-1444-7551","observed_orcids":["https://orcid.org/0000-0003-1444-7551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tom Curran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12009","display_name":"Hedgehog Signaling Pathway Studies","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vismodegib","display_name":"vismodegib","score":1.0},{"id":"https://openalex.org/keywords/medulloblastoma","display_name":"medulloblastoma","score":0.984000027179718},{"id":"https://openalex.org/keywords/pediatric-brain-tumors","display_name":"pediatric brain tumors","score":0.8029999732971191},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.6669999957084656},{"id":"https://openalex.org/keywords/concentration-time-profiles","display_name":"concentration-time profiles","score":0.5630000233650208},{"id":"https://openalex.org/keywords/alpha-1-acid-glycoprotein","display_name":"alpha-1-acid glycoprotein","score":0.9309999942779541},{"id":"https://openalex.org/keywords/drug-binding","display_name":"drug binding","score":0.6169999837875366},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6629999876022339},{"id":"https://openalex.org/keywords/hedgehog-pathway-inhibitors","display_name":"Hedgehog pathway inhibitors","score":0.7210000157356262}],"concepts":[{"id":"https://openalex.org/C2779545874","wikidata":"https://www.wikidata.org/wiki/Q2070286","display_name":"Vismodegib","level":4,"score":0.9542475938796997},{"id":"https://openalex.org/C2780789225","wikidata":"https://www.wikidata.org/wiki/Q1333608","display_name":"Medulloblastoma","level":2,"score":0.6803535223007202},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5377168655395508},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5094719529151917},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4770464301109314},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4724462628364563},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4268672466278076},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.33200642466545105},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.23006895184516907},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.148118793964386},{"id":"https://openalex.org/C2778804307","wikidata":"https://www.wikidata.org/wiki/Q809758","display_name":"Basal cell carcinoma","level":3,"score":0.13427171111106873},{"id":"https://openalex.org/C3019992690","wikidata":"https://www.wikidata.org/wiki/Q92767510","display_name":"Basal cell","level":2,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22451901","doi":"https://doi.org/10.1158/1078-0432.22451901","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451901","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22451901.v1","doi":"https://doi.org/10.1158/1078-0432.22451901.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451901.v1","pdf_url":"https://aacr.figshare.com/ndownloader/files/39902979","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22451901","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_1_-_2_from_Phase_I_Study_of_Vismodegib_in_Children_with_Recurrent_or_Refractory_Medulloblastoma_A_Pediatric_Brain_Tumor_Consortium_Study/22451901","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22451901","doi":"https://doi.org/10.1158/1078-0432.22451901","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451901","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361883236.pdf","grobid_xml":"https://content.openalex.org/works/W4361883236.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2099469211","https://openalex.org/W4361951065","https://openalex.org/W4408150907","https://openalex.org/W2603489900","https://openalex.org/W4361960248","https://openalex.org/W2131928859","https://openalex.org/W2111433192","https://openalex.org/W7160852509","https://openalex.org/W2586065840","https://openalex.org/W4236143131"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"156K,":[3],"Supplementary":[4,61],"Fig.":[5],"S1.":[6],"Concentration-time":[7],"plots":[8],"of":[9,16,49],"the":[10,17,25,28,96],"first":[11,18],"72":[12],"hours":[13],"after":[14],"administration":[15],"vismodegib":[19,51,56,68],"dose":[20],"during":[21],"Course":[22],"1":[23],"to":[24],"patients":[26,87],"in":[27,77,89],"initial":[29],"cohort:":[30],"6":[31],"received":[32,41],"85":[33],"mg/m2":[34,43],"(Figure":[35,44],"A":[36],"&":[37],"B),":[38],"and":[39,54,71],"7":[40],"170":[42],"C":[45],"&D).":[46],"Plasma":[47],"concentrations":[48,70,76],"total":[50,67],"(A,":[52],"C)":[53],"unbound":[55],"(B,":[57],"D)":[58],"were":[59],"measured.":[60],"Fig":[62],"S2.":[63],"The":[64,80,92],"relation":[65],"between":[66],"plasma":[69,75],"alpha-1-acid":[72],"glycoprotein":[73],"(AAGP)":[74],"pediatric":[78],"patients.":[79],"scatter":[81],"plot":[82],"includes":[83],"all":[84],"data":[85],"from":[86,99],"treated":[88],"this":[90],"study.":[91],"solid":[93],"line":[94,98],"represents":[95],"best-fit":[97],"linear":[100],"regression":[101],"analysis":[102],"(R2=":[103],"0.38).":[104]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}